12:00 AM
Jun 09, 2003
 |  BioCentury  |  Product Development

Treating the treatments

Lessons from ASCO

Treating the treatments

While targeted therapies were hot topics at this year's American Society of Clinical Oncology meeting, systemic cancer therapies aren't going to be usurped from their entrenched positions in treatment regimens in the foreseeable future. Thus, companies see large opportunities to develop treatments for the side effects of chemotherapy and radiation therapy, which include chemotherapy-induced nausea and vomiting (CINV) and oral mucositis.

In CINV, incremental improvements in existing treatments may be enough to garner market share, while mucositis is an underserved indication where ice chips are still used.

Published reports have estimated that CINV occurs in 60-80% of patients who do not receive prophylactic anti-emetics. The standard of care is treatment with a serotonin (5-HT3) antagonist and dexamethasone. The antagonist is given intravenously about 30 minutes prior to chemotherapy, and the oral steroid is taken for several days post-chemotherapy.

One of the problems with this regimen is that the effect of the 5-HT3 antagonist may wear off prior to the next day's oral steroid dose.

MGI Pharma Inc. and...

Read the full 859 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >